News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact


> GlaxoSmithKline CEO Emma Walmsley outlined her fix for the company's long-standing pipeline woes. The plan is to give the commercial team a bigger say in pipeline decisions. Article 

> Leo Pharma formed a research collaboration with HitGen. The agreement will see HitGen turn its technology on targets of interest to Leo. Statement 

> Alligator Bioscience expanded its immuno-oncology collaboration with Stanford University. Release 

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.